Paperback
Throughout the text, examples are given to illustrate issues that a clinical laboratory might encounter. While some examples relate to the field of immunosuppressive drug monitoring, the issues are common and relevant to any clinical application. The guidance provided is also applicable to instrumentation made by any manufacturer.
This practical guide covers topics that range from instrument selection and business planning to installation, risk management and validation, and also includes suggestions for future prospects in this developing field.
Features
A concise, easy-to-read guide for clinical scientists who would like to know the best way to set up a mass spectrometry system in their laboratory.
Guidance and anecdotes are the result of the author’s ten years’ experience of clinical mass spectrometry. For the novice and those lacking experience in this area, this type of troubleshooting advice is extremely valuable.
The information provided is applicable to instrumentation from any manufacturer and for any clinical application.
Chapter summaries provide checklists for the main activities that need to be put into action.
Chapter 1 Introduction
Chapter 2 Why Choose Mass Spectrometry?
Chapter 3 Selection of Instrumentation
Chapter 4 Business Planning
Chapter 5 Installation
Chapter 6 Risk Management
Chapter 7 Methodology and Validation
Chapter 8 Standard Operating Procedures
Chapter 9 Future Prospects
Chapter 10 A Blessing and a Curse?
References
Index
Neil Leaver is a clinical scientist with over 30 years’ experience in the National Health Service and 20 years’ experience in the measurement of immunosuppressive drugs used in transplantation.
Following on from an idea developed in 1996, his first mass spectrometer was installed in December 1997 as a development platform for new rapid liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) methods for therapeutic drug monitoring of the immunosuppressive drugs cyclosporin and tacrolimus. In April 1999, following extensive validation and risk analysis, the UK’s first seven-day week MS service for these drugs was introduced.
Today the service operates three clinical instruments providing national services to hospitals in the UK and Eire. In addition, the service has a number of research and development programmes: these include new method development and assessing new hardware for suitability for use in clinical diagnostics.
ILM Guide 2026/27